Sadia Farzana

Dr. Sadia Farzana

Pritzker School of Law, Northwestern University, Chicago, Illinois, USA
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
SFSadia Farzana
Sadia Farzana
FRFrancesco Maria Rossi
Francesco Maria Rossi
KAKatie S. Allen
Katie S. Allen
QLQian Luo
Qian Luo
JWJeff Whittle
Jeff Whittle
BBBernard S. Black
Bernard S. Black
Objective: This study aimed to assess COVID-19 vaccine effectiveness against death (VE), controlling for healthy vaccinee bias. Methods: We link all adult deaths through year-end 2022 in the State of Indiana, U.S.A., to vaccination records and identify which deceased received primary vaccination (measured as either one or two initial doses) and which received one or two booster doses. We measure COVID-19 mortality with the COVID Excess Mortality Percentage (CEMP). CEMP is calculated, for a group defined by various characteristics (age, sex, time period), as COVID-19 deaths divided by non-COVID natural deaths. The CEMP outcome measure accounts for healthy vaccinee bias by using non-COVID natural mortality to control for differences in population health. Results: We find a large healthy vaccinee bias. Controlling for this bias, we find substantial VE for primary vaccination and the first booster dose during the first five vaccine-available calendar quarters, from 1Q2021 through 1Q2022 (end of Omicron infection wave). However, over 2Q–4Q2022, we find no evidence for primary-vaccination VE, and find moderate but statistically insignificant booster VE, which largely wanes by 4Q2022. Conclusions: It is known that by 2Q2022, most people had natural immunity from prior COVID-19 infection. Thus, our results for 2Q–4Q2022 largely reflect comparing hybrid (infection plus vaccination) immunity to infection-only immunity. In this period, we find negligible mortality benefit from primary vaccination, and moderate but waning benefit from a booster dose. Policy Implications: Controlling for healthy vaccinee bias is crucial when estimating VE. We found limited VE against COVID-19 mortality over 2Q–4Q2022, but lacked data for more recent periods.

1 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
FRFrancesco Maria Rossi
Francesco Maria Rossi
VAVladimir A. Atanasov
Vladimir A. Atanasov
SFSadia Farzana
Sadia Farzana
QLQian Luo
Qian Luo
KAKatie Allen
Katie Allen
BBBernard S. Black
Bernard S. Black
COVID-19 mortality risk was small for young people and rose rapidly with age. Dr. Vinay Prasad, the Dirctor of the FDA's Center for Biologics Evaluation and Research (CBER) has questioned the net benefit of COVID-19 vaccination for children and young adults, citing evidence of 10 and perhaps more cases of probable young-adult deaths from vaccine-induced myocarditis. These deaths must be balanced against lives saved in this age group. We estimate how many lives of people aged 15-24 were saved by COVID-19 vaccination over July 2021-March 2022. We use a combination of US national data and linked mortality and vaccination records from Indiana, and several estimation strategies which account for healthy vaccinee bias. There were 1,387 COVID-19 deaths of people aged 15-24 during this period in the US. We estimate that COVID-19 vaccination prevented 1,086-1,532 additional deaths (mean=1,303) in this age group. Encouraging vaccination was a reasonable strategy at the time and was highly effective in hindsight. We caution that these results do not extend to children under 15, who had much lower COVID-19 mortality, or to booster doses (which had limited incremental value for this age group).

9 June 2026 in Medical Care
Verified
Journal Article
Closed access
SFSadia Farzana
Sadia Farzana
AMAli Moghtaderi
Ali Moghtaderi
AYAndy Ye PhD Yuan
Andy Ye PhD Yuan
QLQian (Eric) Luo
Qian (Eric) Luo
VKVinay Md Kini
Vinay Md Kini
BBBernard S. Black
Bernard S. Black
Background: Prior work often finds racial/ethnic differences in mortality following acute myocardial infarction (AMI), but is subject to selection bias. Similar selection issues arise for differences associated with socioeconomic status (SES). Objectives: Re-examine the association between patient race/ethnicity, area-level socioeconomic status (area-SES), and post-AMI mortality using a data source that limits patient selection of hospital or cardiologist, or vice-versa, and which lets us distinguish between-hospital from within-hospital sources of differences. Research Design: We compare mortality disparities with no controls, with controls typical of the prior literature (“typical controls”), and more extensive controls, including hospital, cardiologist, and calendar quarter fixed effects (FEs). Subjects: The study uses a 100% sample of 681,000 Medicare Fee-for-Service patients aged 68+ hospitalized for incident (first) AMI over 2008–2019. Measures: Post-AMI mortality in-hospital, within 30 days after discharge and over periods up to 3 years post-discharge. We study patients with ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (nSTEMI) separately. Results: With no or typical controls, Blacks, Hispanics, and Asians have higher in-hospital mortality than Whites; lower SES also predicts higher mortality. However, higher mortality is substantially explained by between-hospital differences in mortality rates. Longer-term mortality is higher for Black patients, consistent with the importance of post-discharge pathways. Conclusions: Post-AMI disparities in outcomes can be strongly affected by selection effects, especially the tendency for poor and minority persons to be treated at lower-quality hospitals. Disparities measurement and policy discussions should distinguish access-related hospital sorting from within-hospital processes and pay greater attention to post-discharge pathways.

25 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SFSadia Farzana
Sadia Farzana
FRFrancesco Maria Rossi
Francesco Maria Rossi
QLQian Luo
Qian Luo
JWJeff Whittle
Jeff Whittle
KMKevin McGUrk
Kevin McGUrk
BBBernard S. Black
Bernard S. Black
This Supplementary Material provides additional results and methods details for Farzana et al. (2026), Pfizer versus Moderna COVID-19 Vaccine Effectiveness against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana.

1 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
QLQian Luo
Qian Luo
FRFrancesco Maria Rossi
Francesco Maria Rossi
AMAli Moghtaderi
Ali Moghtaderi
SFSadia Farzana
Sadia Farzana
JWJeff Whittle
Jeff Whittle
BBBernard S. Black
Bernard S. Black
COVID-19 killed millions of people worldwide, but rapid vaccine development saved millions of lives. We model lives saved in the U.S., by age range, under three alternative scenarios: (i) no vaccination; (ii) full vaccination (95% vaccination of all persons); and (iii) a faster booster scenario, with 95% booster uptake among those with primary vaccination plus booster update speed matching the actual speed achieved for primary vaccination. There were 983,000 COVID-19 deaths in the U.S. over the pandemic period (March 2020-April 2023); this would have been 1,787,000 with no vaccination (804,000 lives saved). Full vaccination would have saved 62,000 additional lives and faster booster uptake would have saved another 47,000 lives. Mean life-years lost per decedent were 14.70; total life-years saved by vaccination were 14.5 million; full vaccination and faster booster uptake would have saved an additional 1.7 million and 649,000 life years, respectively. Most lives saved from vaccination, or deaths not saved due to lack of full vaccination, were for the middle-aged and elderly, but the percentage of preventable COVID-19 deaths due to partial vaccine uptake was largest for younger persons, due to lower vaccination rates. The effect of partial uptake on life-years lost was largest for the middle aged.

1 January 2024 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
SFSadia Farzana
Sadia Farzana
AOAndrew Owen
Andrew Owen
JMJohn R Meurer
John R Meurer
RARonald Ackermann
Ronald Ackermann
BBBernard S. Black
Bernard S. Black
We extend the Oregon Health Insurance Experiment (OHIE) study of the effects of gaining health insurance by reporting time-series evidence, from difference-indifferences (DiD) analysis of visit-level healthcare records, before and after Medicaid expansion in Wisconsin in 2014 under the Affordable Care Act (ACA). Wisconsin expanded Medicaid to cover childless adults with incomes up to 100% of the federal poverty limit (FPL). We follow these persons over 2011-2022 using electronic health records (EHR) records for a major, Milwaukee-based health system. We compare healthcare use for newly-Medicaid-enrolled childless adults aged 36-64 (treatment group) with a propensity-score-balanced control group of previously enrolled persons. Gaining health insurance leads to a sharp, immediate, rise in health care utilization. Outpatient visit rates for new enrollees roughly double, to levels similar to the control group. ED visit and hospitalization rates jump from well below to well above the control group, but by 2016 fall back to control-group levels. ED visits rise for both visits leading to discharge and visits leading to hospital admission. Medicaid expansion predicts an increase in a range of new diagnoses (e.g. diabetes, microvascular disease, peripheral vascular disease), new medication prescriptions (e.g., diabetes, cholesterol, blood pressure), testing rates (e.g., glucose, HbA1c for diabetics, cholesterol), and lower levels for chronic disease markers (glucose, cholesterol, blood pressure, but no change in macrovascular event rates. Treatment effects are broadly similar across gender, race/ethnicity, and age.